The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yelton, D. E.
Right arrow Articles by Glaser, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yelton, D. E.
Right arrow Articles by Glaser, S. M.

The Journal of Immunology, Vol 155, Issue 4 1994-2004, Copyright © 1995 by American Association of Immunologists

ARTICLES

Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis

DE Yelton, MJ Rosok, G Cruz, WL Cosand, J Bajorath, I Hellstrom, KE Hellstrom, WD Huse and SM Glaser
Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121, USA.

We have increased up to 65-fold the avidity of BR96, a mAb recognizing Lewis Y (Le(y))-related Ags expressed on the surface of many human carcinomas. Libraries of mutations in the complementarity-determining regions (CDRs) of BR96 were constructed in an M13 phage Fab expression vector by codon-based mutagenesis, a method that efficiently introduces large numbers and potentially all combinations of amino acid substitutions. Two mutants that improved the affinity of BR96 to tumor Ag were identified by screening the libraries on carcinoma cell lines. One mutant, M1, at position 97 (Asp to Ala) in CDR3 of the heavy chain, resulted in an 8- to 10-fold improvement in Ag binding, as assessed by ELISA. A second mutant, M2, at position 53 (Gly to Asp) in CDR2 of VH increased binding three- to fivefold. When these mutations were combined, the resulting Fab M3 was improved approximately 30-fold. An additional library was constructed in CDR1 of M1. M4, a mutation with three amino acid substitutions in CDR1, was isolated by screening the library with an enzyme conjugate of synthetic Le(y) tetrasaccharide (sLe(y)). This mutant improved BR96 Fab affinity to sLe(y) an estimated 15- to 20-fold by ELISA, and 14-fold as measured by surface plasmon resonance. The M4 IgG had 65-fold improved avidity to sLe(y) relative to the BR96 IgG. The mutants will be useful for comparison of the efficacy of Abs with different affinities for delivery of cytotoxic agents to tumor cells.


This article has been cited by other articles:


Home page
 ScienceHome page
S. B. Lee, D. T. Mitchell, L. Trofin, T. K. Nevanen, H. Soderlund, and C. R. Martin
Antibody-Based Bio-Nanotube Membranes for Enantiomeric Drug Separations
Science, June 21, 2002; 296(5576): 2198 - 2200.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Salvatore, R. Beers, I. Margulies, R. J. Kreitman, and I. Pastan
Improved Cytotoxic Activity toward Cell Lines and Fresh Leukemia Cells of a Mutant Anti-CD22 Immunotoxin Obtained by Antibody Phage Display
Clin. Cancer Res., April 1, 2002; 8(4): 995 - 1002.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Foote and H. N. Eisen
Breaking the affinity ceiling for antibodies and T cell receptors
PNAS, September 26, 2000; 97(20): 10679 - 10681.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Beers, P. Chowdhury, D. Bigner, and I. Pastan
Immunotoxins with Increased Activity against Epidermal Growth Factor Receptor vIII-expressing Cells Produced by Antibody Phage Display
Clin. Cancer Res., July 1, 2000; 6(7): 2835 - 2843.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Wu, G. Beuerlein, Y. Nie, H. Smith, B. A. Lee, M. Hensler, W. D. Huse, and J. D. Watkins
Stepwise in vitro affinity maturation of Vitaxin, an alpha vbeta 3-specific humanized mAb
PNAS, May 26, 1998; 95(11): 6037 - 6042.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Rosok, M. Eghtedarzadeh-Kondri, K. Young, J. Bajorath, S. Glaser, and D. Yelton
Analysis of BR96 Binding Sites for Antigen and Anti-Idiotype by Codon-Based Scanning Mutagenesis
J. Immunol., March 1, 1998; 160(5): 2353 - 2359.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. A. Burks, G. Chen, G. Georgiou, and B. L. Iverson
In vitro scanning saturation mutagenesis of an antibody binding pocket
PNAS, January 21, 1997; 94(2): 412 - 417.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. J. Rosok, D. E. Yelton, L. J. Harris, J. Bajorath, K.-E. Hellstrom, I. Hellstrom, G. A. Cruz, K. Kristensson, H. Lin, W. D. Huse, et al.
A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab
J. Biol. Chem., September 13, 1996; 271(37): 22611 - 22618.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Thomas, S. I. Patenaude, C. R. MacKenzie, R. To, T. Hirama, N. M. Young, and S. V. Evans
Structure of an Anti-blood Group A Fv and Improvement of Its Binding Affinity without Loss of Specificity
J. Biol. Chem., January 11, 2002; 277(3): 2059 - 2064.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Luo, G. Canziani, G. Cunto-Amesty, and T. Kieber-Emmons
A Molecular Basis for Functional Peptide Mimicry of a Carbohydrate Antigen
J. Biol. Chem., May 19, 2000; 275(21): 16146 - 16154.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.